» Authors » Irene Ruiz-DeDiego

Irene Ruiz-DeDiego

Explore the profile of Irene Ruiz-DeDiego including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 93
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Keifman E, Ruiz-DeDiego I, Pafundo D, Paz R, Solis O, Murer M, et al.
Br J Pharmacol . 2019 Mar; 176(13):2146-2161. PMID: 30895594
Background And Purpose: L-DOPA-induced dyskinesia (LID) remains a major complication of L-DOPA therapy in Parkinson's disease. LID is believed to result from inhibition of substantia nigra reticulata (SNr) neurons by...
2.
Ruiz-DeDiego I, Fasano S, Solis O, Garcia-Montes J, Brea J, Loza M, et al.
Sci Rep . 2018 Oct; 8(1):15381. PMID: 30337665
Increasing evidence supports a close relationship between Ras-ERK1/2 activation in the striatum and L-DOPA-induced dyskinesia (LID). ERK1/2 activation by L-DOPA takes place through the crosstalk between D1R/AC/PKA/DARPP-32 pathway and NMDA/Ras...
3.
Garcia-Montes J, Solis O, Enriquez-Traba J, Ruiz-DeDiego I, Drucker-Colin R, Moratalla R
Mol Neurobiol . 2018 Sep; 56(6):4037-4050. PMID: 30259400
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor...
4.
Hernandez L, Castela I, Ruiz-DeDiego I, Obeso J, Moratalla R
Mov Disord . 2017 Mar; 32(4):530-537. PMID: 28256089
Background: Long-term levodopa (l-dopa) treatment is associated with the development of l-dopa-induced dyskinesias in the majority of patients with Parkinson disease (PD). The etiopathogonesis and mechanisms underlying l-dopa-induced dyskinesias are...
5.
Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo J, Moratalla R
Biol Psychiatry . 2014 May; 77(2):95-105. PMID: 24857398
Background: Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway as well as FosB and dynorphin-B expression mediated by dopamine D1 receptor stimulation in the development of 3,4-dihydroxyphenyl-L-alanine...